Nora Ventosa's Projects

  • FEDER Nanbiosis. Convenio entre el CSIC y el Ministerio Economia, Industria y Competividad para el proyecto compra e instalación y puesta a punto de equipamiento y laboratorios de producción. NANBIOSIS-U2,4,6 Y 8. Mineco. Fondos FEDER. POCInt 2014-2020. Convenio OTR03323. 20/09/2017-31/12/2018.
  • FONBIO. Fluorescent organic nanoparticles for bioimaging. ACCIÓ. TECSPR17-1-0035. 16/6/2018-15/6/2020.
  • MAGIC. Magnetically induced drug release from quatsomes. ACCIÓ. TECSPR16-1-0055. 16/09/2017-15/09/2019.
  • MOTHER: Molecule-based materials and supramolecular organizations for therapy, diagnosis and tissue engineering. MAT2016-80826-R, Ministerio de Economia y Competitividad; 01/01/2017 - 31/12/2019; PI: Jaume Veciana and Nora Ventosa.
  • FLOWERS: New fluorescent water-dispersable colloidal nanoparticles for advanced bio-imaging and theranostic applications; 01/03/2017-28/02/2019
  • SMART-4-FABRY: Smart multifunctional GLA-nanoformulation for Fabry disease; H2020-NMBP-2016-2017/H2020-NMBP-2016-two-stage: 720942; 01/01/2017-31/12/2020.
  • NANONAFRES: Preclinics and clinics studies of application to nanovesicles (quatsomes) with EGF in venous ulcer; COMDRI15-1-0023; 15/10/2016-14/10/2019.
  • NANO4DERM: Nanocapsules containing actives for the topic treatment of dermatological diseases; RTC-2016-4567-1; 01/10/2016-31/11/2019.
  • REACTOR: High-pressure reactor for studying processes of preparation of nanostructured materials with compressed fluids; CSIC13-4E-2370.
  • UNDERLIPIDS: Solid lipidic nanoparticles for the subcutaneous administration of antitumoral marine compounds; RTC-2015-3303-1; 24/02/2015-31/12/2018.
  • LIPOCELL: Functionalized nanoliposomes for the development of therapies for intracellular-based diseases. Application to Fabry disease and homozygous familial hypercholesterolemia; 01/12/2014-30/11/2016.
  • TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases; RTC-2014-2207-1; 28/01/2014-31/12/2017.
  • BE-WELL: Bio- and Electro-active molecule-based materials for improving health andsocietal WELLbeing. CTQ2013-40480-R, Ministerio de Economia y Competitividad; 01/01/2014 - 3106/2017; PI: Jaume Veciana and Concepció Rovira.
  • BERENICE: Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE; FP7-HEALTH-2012-INNOVATION-1-305937; 01/09/2012-31/08/2017.
  • NANOSTEM: Targeting Combined Therapy to Cancer Stem Cells. IP: Nora Ventosa. Coordinator: Simó Schwartz, Hospital Universitari Vall de Hebrón, Spain. EU European Innovative RTD Projects Proposals in Nanomedicine, EuroNanoMed. Start/End date:01/01/2010-31/12/2012.
  • NANOFABRY: Development of nanomedicines for enzymatic replacement therapy in Fabry Disease. IP: Jaume Veciana / Nora Ventosa. La Marató TV3. Coordinator: Simó Schwartz, Hospital Universitari Vall de Hebrón. Spain. Start/End date: 1/01/2011-31/12/2014.
  • ORALBEADS: Desarrollo de dispersiones sólidas micro/nanoestructuradas para administración oral de compuestos marinos antitumorales.  IP: Nora Ventosa; Coordinator: PHARMA MAR, S.A. Proyecto INNPACTO. IPT-2011-0754-900000: MICINN. Start/End date: 1/01/2011-31/12/2014.
  • DENDRIA. IP: Nora Ventosa. Coordinator: NOSCIRA. Proyecto CENIT CDTI.Start/End date: 1/06/2010-30/06/2013.
  • VITILIGO. IP: Nora Ventosa. Coordinator: 3P BIOPHARMACEUTICALS SL. Proyecto INNPACTO IPT-010000-2010-22 MICINN. Start/End date:1/01/2010-31/12/2012.